Approved indications of lipo-PGE(1) in Japan

被引：4

作者：

Hoshi, K

机构：

[1] Institute of Medical science, ST. Marianna University, Kawasaki

来源：

ADVANCED DRUG DELIVERY REVIEWS | 1996年 / 20卷 / 2-3期

关键词：

lipo-PGE(1); chronic arterial occlusive disease; peripheral vascular disturbances; connective tissue disease; vibration syndrome; diabetic neuropathy; skin ulcer;

D O I：

10.1016/0169-409X(95)00120-V

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

For its peripheral vascular dilating effect and platelet agglutination inhibitory activity, prostaglandin E(1) is used in the treatment of diseases which are likely to cause peripheral circulatory failure or thrombus. In Japan, lipo-PGE(1), which was developed to give it a target-directed nature by modifying the conventional PGE(1), has been used and found to be useful in clinical practice. In this report, we attempt to describe the clinical benefits of lipo-PGE(1) focusing on the diseases which have been approved for its indications.

引用

页码：171 / 176

页数：6

共 17 条

[1]

AGISHI Y, 1986, RINSHO IYAKU, V2, P67

[2]

CARLSON LA, 1976, LANCET, V2, P810

[3] CAPILLARY NUMBER AND PERCENTAGE CLOSED IN HUMAN DIABETIC SURAL NERVE [J].